Patients with NSCLC show high levels of tumor markers CEA and Cyfra21-1 [29–31], while they are not specifically overexpressed at early stage, which facilitates the establishment of new and effective diagnostic or prognostic biomarkers. Here, CEACAM5 is linked to non-small cell lung carcinoma.